Print

Dominantly Inherited Alzheimer Network (DIAN) and CSF Biomarker Discovery in Familial Alzheimer's Disease (FAD)

Purpose

Research suggests that brain changes may occur years before actual Alzheimer's symptoms are detected. The major goal of DIAN is to study these changes in people who carry an AD mutation to determine how the disease process develops before there are any symptoms. Ultimately, knowledge gained from DIAN may lead to tests that detect people who still are normal but are at very high risk of developing dementia caused by AD. All DIAN participants will be members of families with dominantly inherited AD caused by a known mutation and may be ideal candidates to participate in future studies of drugs that have the potential to halt the AD process and prevent dementia. For more information, please contact: David Wharton at (310) 794-0355 or John Ringman, MD, MS at (310) 794-3231.

Sponsor: PHS/U.S. National Institute on Aging (NIA) and Wyeth Pharmaceuticals, Inc.
Principal Investigator: John Ringman, MD, MS
Co-Investigators: Karen Gylys, PhD, Gary Small, MD, Jorge Barrio, MD, and Vladimir Kepe, PhD.

Contact: David Wharton at (310) 794-0355 or John Ringman, MD, MS at (310) 794-3231 to participate in this study or for more information.